This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ofatumumab parenteral


Injections of ofatumumab.

Drugs List

  • KESIMPTA SENSOREADY 20mg/0.4ml solution for injection pre-filled pen
  • ofatumumab 20mg/0.4ml solution for injection pre-filled pen
  • Therapeutic Indications


    Treatment of relapsing-remitting multiple sclerosis

    Treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease defined by clinical or imaging features.



    Initial dose: 20mg at weeks 0, 1 and 2.

    Maintenance dose: 20mg monthly starting at week 4.

    Additional Dosage Information

    Missed doses
    If a dose is missed, administer the missed dose as soon as possible. Administer subsequent doses at the recommended intervals.


    For subcutaneous injection only.

    The usual sites for subcutaneous injections are the abdomen, the thigh and the upper outer arm.

    The first dose should be administered under guidance of a specialist.


    Children under 18 years
    Severe immunosuppression
    Severe infection
    Within 2 weeks of inactivated vaccines
    Within 4 weeks of live viral or bacterial vaccination
    Malignant neoplasm

    Precautions and Warnings

    History of hepatitis B
    History of progressive multifocal leukoencephalopathy (PML)

    Avoid live vaccines during treatment and until immune recovery
    Before initiating screen all patients for hepatitis B infection
    Hepatitis B: Refer prior to initiation to liver disease specialist
    Treat and control infections prior to commencing therapy
    Treatment to be initiated by specialist
    Record name and batch number of administered product
    Evaluate patient's immune status before initiation
    Antibody response to vaccines may be reduced
    Risk of developing opportunistic infections
    Discontinue if Progressive multifocal leukoencephalopathy (PML) develops

    B-cell median time recovery to lower limit of normal or baseline value is 24.6 weeks post treatment discontinuation.

    HBV screen will need to include hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb), these can be complemented with other appropriate markers.

    Severely immunocompromised patients cannot be treated with ofatumumab until condition resolves. It is not recommend to use other immunosuppressants concomitantly except corticosteroids for the treatment of symptomatic relapses.

    Pregnancy and Lactation


    Use ofatumumab with caution during pregnancy.

    The manufacturer recommends that ofatumumab should be avoided during pregnancy unless the benefit to the mother outweighs the risk of the foetus. Animal studies indicate that ofatumumab may cross the placenta and cause foetal B-cell depletion.

    Manufacturer recommends that live vaccinations should be avoided in infants of mothers treated with ofatumumab during pregnancy until immune recovery.


    Use ofatumumab with caution during breastfeeding.

    The manufacturer states that the use of ofatumumab during breastfeeding has not been studied and it is unknown if ofatumumab is excreted in human milk. A risk to breastfed newborns cannot be excluded due to low concentrations of immunoglobulin G following birth. Breastfeeding can begin immediately if the patient was treated with ofatumumab up to the last few months of pregnancy.


    Advise patient that injection-related reactions can occur generally within 24 hours following the first dose.

    Advise patient to report signs or symptoms of infection.

    Side Effects

    Decrease in blood immunoglobulin M
    Injection site reactions
    Oral herpes
    Upper respiratory tract infection
    Urinary tract infections


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: June 2021

    Reference Sources

    Summary of Product Characteristics: Kesimpta 20 mg solution for injection in pre-filled pen. Novartis Pharmaceuticals UK Ltd. Revised April 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.